KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Depreciation & Amortization - Total (2022 - 2026)

Pacific Biosciences Of California has reported Depreciation & Amortization - Total over the past 4 years, most recently at $2.7 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization - Total fell 3.27% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $13.0 million, down 5.62%, while the annual FY2025 figure was $13.0 million, 5.62% down from the prior year.
  • Depreciation & Amortization - Total for Q4 2025 was $2.7 million at Pacific Biosciences Of California, up from $2.5 million in the prior quarter.
  • Over five years, Depreciation & Amortization - Total peaked at $5.1 million in Q1 2025 and troughed at $2.3 million in Q1 2022.
  • A 4-year average of $3.0 million and a median of $2.8 million in 2023 define the central range for Depreciation & Amortization - Total.
  • On a YoY basis, Depreciation & Amortization - Total climbed as much as 58.36% in 2025 and fell as far as 41.31% in 2025.
  • Year by year, Depreciation & Amortization - Total stood at $2.5 million in 2022, then increased by 18.48% to $3.0 million in 2023, then fell by 5.68% to $2.8 million in 2024, then fell by 3.27% to $2.7 million in 2025.
  • Business Quant data shows Depreciation & Amortization - Total for PACB at $2.7 million in Q4 2025, $2.5 million in Q3 2025, and $2.7 million in Q2 2025.